175 related articles for article (PubMed ID: 24966622)
1. Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.
Xue JH; Zhu HH; Wang J; Chen Z
World J Gastroenterol; 2014 Jun; 20(23):7505-13. PubMed ID: 24966622
[TBL] [Abstract][Full Text] [Related]
2. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
Vujosevic S; Tempesta D; Noventa F; Midena E; Sebastiani G
Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668
[TBL] [Abstract][Full Text] [Related]
4. Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review.
Raza A; Mittal S; Sood GK
J Viral Hepat; 2013 Sep; 20(9):593-9. PubMed ID: 23910642
[TBL] [Abstract][Full Text] [Related]
5. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
Lai CH; Yang YH; Chen PC; King YC; Liu CY
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):191-198. PubMed ID: 29210149
[TBL] [Abstract][Full Text] [Related]
6. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
Panetta JD; Gilani N
Aliment Pharmacol Ther; 2009 Sep; 30(6):597-602. PubMed ID: 19549263
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
[TBL] [Abstract][Full Text] [Related]
8. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
Okuse C; Yotsuyanagi H; Nagase Y; Kobayashi Y; Yasuda K; Koike K; Iino S; Suzuki M; Itoh F
World J Gastroenterol; 2006 Jun; 12(23):3756-9. PubMed ID: 16773695
[TBL] [Abstract][Full Text] [Related]
10. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.
Saito H; Ebinuma H; Nagata H; Inagaki Y; Saito Y; Wakabayashi K; Takagi T; Nakamura M; Katsura H; Oguchi Y; Ishii H
Liver; 2001 Jun; 21(3):192-7. PubMed ID: 11422782
[TBL] [Abstract][Full Text] [Related]
11. Retinal complications during interferon therapy for chronic hepatitis C.
Kawano T; Shigehira M; Uto H; Nakama T; Kato J; Hayashi K; Maruyama T; Kuribayashi T; Chuman T; Futami T; Tsubouchi H
Am J Gastroenterol; 1996 Feb; 91(2):309-13. PubMed ID: 8607498
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
Wu CM; Su FH; Muo CH; Huang JC; Wu MM; Yeh CC
Viruses; 2021 Mar; 13(3):. PubMed ID: 33799370
[TBL] [Abstract][Full Text] [Related]
13. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
Kim ET; Kim LH; Lee JI; Chin HS
Jpn J Ophthalmol; 2009 Nov; 53(6):598-602. PubMed ID: 20020238
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C and interferon-associated retinopathy: a case report.
Van Wie AM
Optometry; 2011 Dec; 82(12):739-43. PubMed ID: 22108545
[TBL] [Abstract][Full Text] [Related]
15. Retinopathy associated with pegylated interferon and ribavirin causing permanent visual impairment in a patient with chronic hepatitis C.
Moisseiev E; Goldenberg D; Kurtz S
Ophthalmic Surg Lasers Imaging; 2011 Sep; 42 Online():e91-3. PubMed ID: 21899250
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
17. Is screening for interferon retinopathy in hepatitis C justified?
Cuthbertson FM; Davies M; McKibbin M
Br J Ophthalmol; 2004 Dec; 88(12):1518-20. PubMed ID: 15548803
[TBL] [Abstract][Full Text] [Related]
18. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791
[TBL] [Abstract][Full Text] [Related]
19. [A case report of interferon-associated retinopathy].
Sobolewski P; Lapiński T
Klin Oczna; 1999; 101(3):213-6. PubMed ID: 10526448
[TBL] [Abstract][Full Text] [Related]
20. Should we investigate retinopathy in chronic hepatitis C patients receiving treatment with interferon?
Aoufi Rabih S; Alfaya Muñoz LB; Fidalgo Broncano A; Villanueva Hernández R; González Carro P; Pérez Roldán F
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):242-3. PubMed ID: 24366452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
